Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)

This study has been approved by the Yorkshire and The Humber-Bradford Leeds Research Ethics Committee (Reference: 21/YH/0305, IRAS: 297060, January 2022). The results will be presented in national and international conferences, published in peer-reviewed journals and will be communicated to relevant stakeholders. A plain English report will be shared with the study participants, patients' organisations and media.TRIAL REGISTRATION NUMBER: ISRCTN 12238218 (Amy Ackroyd NIHR CPMS Team).PMID:36351720 | DOI:10.1136/bmjopen-2022-068580

Source: Cancer Control - November 9, 2022 Category: Cancer & Oncology Authors: Jim Zhong Sarah Brown Maria Serra Pam Shuttleworth Peter Bownes Christopher Thompson Rachel Reed Kimberley Reeves Michael Dubec Damien McHugh Cynthia Eccles Robert Chuter Yat Man Tsang N Jane Taylor Catharine West David Buckley Andrew Scarsbrook Ananya Ch Source Type: research